id=241160711 The prominent players of global Cattle & porcine/swine reproductive diseases market are Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmBH (Germany ...

The global ruminant vaccines market, valued at USD 3.51 billion in 2023, is projected to grow significantly at a compound annual growth rate (CAGR) of 6.95% from 2024 to 2032. Read the Market Summary ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

The global Cattle & Porcine/Swine Reproductive Diseases market is expected to grow to USD 975.8 Million by 2029, up from USD ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

In this report, the cattle & porcine/swine reproductive diseases ... driving the demand for more effective vaccines and treatments. Additionally, increased efforts in research and development ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

The vaccine debate is not new and, although it has intensified in recent years due to the COVID-19 pandemic, has been around since vaccines were first created. There is a wealth of research ...

The animal health wing of drug maker Pfizer has launched what it bills as Canada’s first vaccine labelled for prevention of bovine respiratory syncytial virus (BRSV) in cattle. The three-way ...